# SSC-COVID in Patients After COVID-19

> **NCT05233553** · — · COMPLETED · sponsor: **University Hospital Tuebingen** · enrollment: 64 (actual)

## Conditions studied

- Secondary Sclerosing Cholangitis
- COVID-19

## Interventions

- **OTHER:** control of liver enzymes

## Key facts

- **NCT ID:** NCT05233553
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2022-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05233553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05233553, "SSC-COVID in Patients After COVID-19". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05233553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*